

·综述·

## 转移性脊柱肿瘤的手术并发症和预防策略

胡宏志<sup>1</sup> 杨文博<sup>1</sup> 邓翔天<sup>2</sup> 王佰川<sup>1</sup> 张志才<sup>1</sup> 刘建湘<sup>1</sup> 吴强<sup>1</sup> 邵增务<sup>1</sup>

**【摘要】** 随着肿瘤综合治疗水平的提高,癌症患者的平均预期寿命得到延长,转移性脊柱肿瘤的发病率也越来越高。转移性脊柱肿瘤作为一种全身性疾病,需要多学科的治疗方法。其中,手术治疗是重要组成部分,可以显著缓解疼痛,恢复脊柱稳定性,降低脊髓压迫的可能性,显著改善患者的生活质量。然而,由于这些患者的健康状况较差,手术治疗会增加围手术期并发症的风险。充分认识和了解可能发生的并发症原因和预防策略有助于降低不必要并发症的发生。本文重点综述转移性脊柱肿瘤手术相关的并发症、潜在的危险因素及预防策略,为脊柱转移瘤患者的治疗提供一定的参考价值。

**【关键词】** 脊柱肿瘤; 转移性肿瘤; 外科治疗; 并发症; 危险因素

**Surgical complications and prevention strategies for metastatic spinal tumors** Hu Hongzhi<sup>1</sup>, Yang Wenbo<sup>1</sup>, Deng Xiangtian<sup>2</sup>, Wang Baichuan<sup>1</sup>, Zhang Zhicai<sup>1</sup>, Liu Jianxiang<sup>1</sup>, Wu Qiang<sup>1</sup>, Shao Zengwu<sup>1</sup>. <sup>1</sup>Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; <sup>2</sup>School of Medicine, Nankai University, Tianjin 300071, China

Corresponding author: Shao Zengwu, Email: szwpro@163.com

**【Abstract】** With the improvement of comprehensive treatment for cancer, the average length of life expectancy is increased, and the incidence of metastatic spinal tumors is increasing. As a systemic disease, metastatic spinal tumor requires multidisciplinary treatment. Among which, surgical treatment is an important part, which can significantly relieve pain, restore spinal stability, reduce the possibility of spinal cord compression, and significantly improve the quality of life of patients. However, surgery increases the risk of perioperative complications due to the poor health of these patients. Fully understanding the causes of the possible complications and prevention strategies might help reduce the incidence of unnecessary complications. This review article focuses on the complications, potential risk factors and prevention strategies related to the surgery of metastatic spinal tumor, providing a certain reference value for the treatment of patients with spinal metastatic tumor.

**【Key words】** Spinal tumor; Metastatic tumor; Surgical treatment; Complication; Risk factor; Prevention strategy

脊柱是仅次于肺和肝脏之外第三最常见的转移部位,也是最常见的骨转移部位<sup>[1-2]</sup>。随着肿瘤综合治疗水平的提高,癌症患者的平均预期寿命得到延长,转移性脊柱肿瘤的发病率也越来越高<sup>[3]</sup>。据估计,在5~30%的原发性癌症中存在脊柱转移,最常见的原发癌为乳腺癌、前列腺癌和肾癌<sup>[4]</sup>。转移性肿瘤可累及椎体及其附件,导致病理性骨折、脊髓压迫或脊柱不稳定,从而引起严重疼痛和脊髓压迫,最终降低癌症患者的生活质量和预期寿命<sup>[5]</sup>。

转移性脊柱肿瘤的治疗是多学科的,包括放射治疗,如:

常规/立体定向体放射治疗(Stereotactic Body Radiation Therapy, SBRT)、化疗、免疫治疗(靶向治疗)、手术治疗(微创治疗和开放手术治疗)等<sup>[6]</sup>。其中,手术治疗是转移性脊柱肿瘤患者治疗的重要组成部分<sup>[3]</sup>。手术治疗可以显著缓解疼痛,恢复脊柱稳定性,降低脊髓压迫的可能性,显著改善患者的生活质量<sup>[7-8]</sup>。然而,由于这些患者的健康状况较差,手术治疗会增加围手术期并发症的风险<sup>[9-10]</sup>。据报道,在接受脊柱转移手术的患者中,并发症的发生率从10%到66.7%不等<sup>[10-22]</sup>。术后并发症不仅给患者及家属带来了沉重的经济和心理负担,也给社会医疗系统带来了沉重的负担。充分认识和了解可能发生的并发症原因和预防策略有助于降低不必要并发症的发生。本文重点综述转移性脊柱肿瘤手术相关的并发症、潜在的危险因素及预防策略,为脊柱转移瘤患者的治疗提供一定的参考价值。

### 一、资料与方法

分别使用中文检索词:“癌症”、“转移瘤”、“脊柱”、“手术

DOI: 10.3877/cma.j.issn.2096-0263.2021.01.010

基金项目:科技部国家重点研发计划资助项目(No.2016YFC1100100);国家自然科学基金重大研发计划资助项目(NO.91694204)

作者单位:430022 武汉,华中科技大学同济医学院附属协和医院骨科<sup>1</sup>; 300071 天津,南开大学医学院<sup>2</sup>

通信作者:邵增务, Email: szwpro@163.com

胡宏志和杨文博对本文有同等贡献

治疗”、“并发症”在中国知网(China National Knowledge Internet, CNKI)及万方数据库检索相关文献;并以英文检索词“Cancer”, “Metastasis”, “Spine”, “Surgery”及“Complications”在PubMed、Web of Science 和 Embase 数据库进行检索,查找从2010年至2020年所有的相关文献,并同时纳入参考文献中的相关文献。文献纳入标准:(1)中文或英文文献;(2)文献类型为临床或成人标本试验研究;(3)研究内容为与脊柱转移瘤治疗相关并发症的文献。排除标准:(1)重复研究的文献;(2)无法获取全文的文献;(3)质量较低、证据等级不高的文献。共获得英文文献1 260篇、中文253篇,根据纳入及排除标准最终选取英文文献124篇,中文文献2篇(图1)。

## 二、治疗原则

目前,转移性脊柱肿瘤的治疗通常采取多学科的治疗方法来维持或改善患者的生存质量,但总体治疗效果仍不理想<sup>[23]</sup>。大部分患者的生存期较短,通常不到一年<sup>[24-27]</sup>。其治疗目标是减轻疼痛,预防或缓解脊髓压迫,保持或恢复神经功能和

脊柱稳定性<sup>[24,28]</sup>。对于预后极差的患者,非手术治疗(放疗、化疗、生物治疗等)或微创姑息治疗、椎体成形术或椎体后凸成形术在缓解疼痛方面取得了令人满意的效果<sup>[29]</sup>。对于脊柱不稳定、畸形、进行性神经功能障碍、脊髓受压严重、对非手术治疗无效的顽固性疼痛以及预期寿命超过3~6个月的患者,必须考虑手术治疗<sup>[30-32]</sup>。了解手术治疗潜在的并发症及其危险因素对权衡手术干预的风险至关重要<sup>[33]</sup>。以下将探讨转移性脊柱肿瘤围术期常见的相关并发症及其危险因素,并强调并发症的预防策略(表1)。

## 三、常见手术并发症与预防策略

### (一)术中并发症

1. 脊髓和神经根损伤:在转移性脊柱手术中,神经系统并发症的发生率从0.6%到14.5%不等<sup>[10,18,34-35]</sup>。常见的神经并发症包括脊髓、马尾和神经根损伤,导致永久性或暂时性的神经功能障碍,如截瘫、偏瘫和感觉功能障碍等<sup>[14,17,21-22,34,36]</sup>。除了手术过程中对神经的直接损伤外,供应脊髓的神经根动脉损伤会影响脊髓的灌注,从而使脊髓面临缺血性损伤的危险<sup>[29]</sup>。如Adamkiewicz动脉的损伤可能导致神经功能障碍,因为它为脊髓提供了重要的灌注来源,当进行下胸椎肿瘤切除时,应特别注意此动脉,无意中结扎可能导致脊髓缺血和截瘫<sup>[37]</sup>。此外,术后的硬膜外血肿形成可造成脊髓和神经根压迫,也会引起严重的神经功能障碍<sup>[29]</sup>。

术前常使用高剂量类固醇以减少创伤性脊髓水肿和潜在的肿瘤压迫<sup>[38]</sup>。术中神经电生理监测可对神经结构的功能完整性进行识别和实时监测<sup>[39]</sup>。在神经损伤的可逆阶段及早发现可以迅速纠正原因并避免造成永久性的损害。一旦电生理监测电位发生变化,手术医生和麻醉师应迅速作出反应。手术医生应注意是否存在可逆性压迫,并及时解除压迫。麻醉医生应确定是否是麻醉剂的影响,血压是否足以维持脊髓灌注。术后可人为提高患者血压水平,以维持脊髓灌注,并可给予类固醇激素<sup>[40]</sup>。在转移性脊柱肿瘤手术中,常常需要牺牲神经根来切除肿瘤<sup>[37]</sup>。如果遇到颈神经根或腰




图1 纳入文献流程图

表1 转移性脊柱肿瘤的常见手术并发症和预防策略

手术并发症类型	预防策略
<b>术中并发症</b>	
脊髓和神经根损伤	术前:高剂量类固醇;术中:神经电生理监测;
大量出血	术后:维持脊髓灌注、类固醇激素; 术前:纠正凝血功能障碍、血管栓塞术、抗纤溶药物、低体温预防;术中:肿瘤血管结扎、双极电凝血、止血药品;
硬脊膜损伤和脑脊液漏	术后:密切监测血压和引流量的变化; 术中:仔细分离肿瘤与硬膜的粘连、避免使用尖锐的器械、分离前彻底止血、直视下谨慎操作等;
<b>术后并发症</b>	
手术部位感染	术前:戒烟、纠正营养不良、控制血糖、预防使用抗生素;术中:遵守严格无菌操作原则、控制手术时间和术中出血量、严密缝合不留死腔;
静脉血栓栓塞	术后:术后行放疗的间隔时间至少一周; 术后:抬高双侧下肢、物理预防(足底静脉泵、间歇充气加压装置、弹力袜等)、鼓励患者主动在床上做足踝部和
内固定失败	关节的主动屈伸运动,争取早日下床活动、早期预防性应用抗凝剂; 术中:合理设计和选择内固定装置和固定方式;术后:早期下床活动,密切随访;
肿瘤复发	术后:对于富血供的原发肿瘤患者术后应密切随访。

神经根受压,则不建议牺牲神经根,因为这种手术本质上是姑息性的。然而在胸椎,除T<sub>1</sub>外,胸椎神经根结扎通常能被患者很好地耐受,而且不会造成明显的术后神经功能障碍<sup>[37]</sup>。

2.大量出血:术中过多的失血会严重影响术区视野,延长手术时间,导致围手术期并发症增加,如严重的心脏不良事件、术后凝血障碍和急性肺损伤等<sup>[41-42]</sup>。据文献报道,转移性脊柱肿瘤术中出血量平均2 180 ml<sup>[43-47]</sup>,严重时可达5 000 ml以上<sup>[48]</sup>。影响术中出血量的因素有:肿瘤的病理类型、肿瘤的大小、浸润范围、手术时间及手术方式等<sup>[49]</sup>。其中,原发肿瘤的类型是判断术中出血量的关键因素。对于血管丰富的肿瘤如转移性肾细胞癌、肝细胞癌和甲状腺癌等,破坏肿瘤包膜常常导致持续出血<sup>[37,50]</sup>。此外,血液系统恶性肿瘤、肝癌及使用抑制骨髓药物的患者易发生凝血功能障碍,术中发生出血并发症的风险尤其高<sup>[40]</sup>。

对于转移性脊柱肿瘤患者,值得注意的是这些患者出血的主要原因包括凝血功能障碍以及术中操作不当导致血管损伤<sup>[40]</sup>。目前,减少术中失血的常规措施包括:凝血功能的评估和纠正、术前栓塞术、抗纤溶药物使用、低体温预防、术中肿瘤血管结扎、使用双极电凝止血以及止血药品的使用等<sup>[51]</sup>。对于富血供的原发肿瘤为肾细胞癌、滤泡性甲状腺癌、神经内分泌肿瘤,以及术前影像学检查怀疑富血供肿瘤的患者可考虑术前栓塞<sup>[40]</sup>。对于术后出现严重或持续的低血压和/或贫血,应怀疑有隐匿性血管损伤,建议使用CT血管造影进行检查<sup>[42]</sup>。总之,制定充分的术前准备与周密的手术计划是避免大量出血发生的关键。

3.硬脊膜损伤和脑脊液漏:在脊柱退行性手术中,发生意外的硬脊膜撕裂的发生率为0.3%~35%<sup>[52-55]</sup>。转移性脊柱肿瘤的转移灶可能与硬脊膜紧密粘连,术中更易发生硬脊膜损伤<sup>[56]</sup>。此外,放疗会使硬膜外纤维化、粘连和硬脊膜变薄显著增加硬脊膜撕裂的风险<sup>[29]</sup>。大多数意外的硬脊膜撕裂可在术中被识别和处理,不需要再次手术或进一步的干预,但值得注意的是其导致的术后脑脊液漏及与脑脊液漏相关的并发症,如伤口感染<sup>[57-59]</sup>、低颅压症<sup>[60]</sup>、颅内蛛网膜下腔出血<sup>[61-63]</sup>、蛛网膜炎<sup>[64-65]</sup>、神经根卡压<sup>[66-67]</sup>、脑膜炎<sup>[68]</sup>及硬膜内肿瘤的播散<sup>[40]</sup>等。

许多硬脊膜损伤可以通过基本的外科原则来预防,如仔细分离肿瘤与硬膜粘连、避免使用尖锐的器械分离硬膜、分离前彻底止血、直视下谨慎操作等<sup>[69]</sup>。近年来,超声骨刀已经逐渐被引入脊柱外科,由于其拥有较大的骨切割精度和避免损伤周围软组织的潜力。但是,超声骨刀在脊柱手术中的安全性和有效性尚未得到很好的证实,有研究认为超声截骨术不太可能穿透硬脊膜<sup>[70]</sup>,但另一些研究者发现超声骨刀也能引起医源性硬脊膜撕裂<sup>[71]</sup>。需要注意的是,转移性脊柱患者更容易出现术后脑脊液漏,原因包括:营养不良、长期使用高剂量类固醇或需要辅助放疗等<sup>[69]</sup>。持续的脑脊液漏导致住院时间延长,而且需要额外的干预,增加了医疗费用<sup>[72]</sup>。因此,早期有效的预防、识别和治疗术后脑脊液漏是避免一系列相关不良后果发生的关键<sup>[69]</sup>。

## (二)术后并发症

1.手术部位感染(Surgical site infection, SSI): SSI是转移性脊柱肿瘤最常见的术后并发症之一<sup>[6,73]</sup>。转移性脊柱肿瘤患者术后SSI的发病率是一般脊柱手术平均发生率的8~10倍<sup>[12,73-75]</sup>。发生SSI的患者治疗的经济成本明显高于未发生SSI的患者,住院时间延长是主要原因<sup>[1]</sup>。平均住院时间增加了100%,约为4周<sup>[1,75]</sup>。此外,SSI还会影响转移性脊柱肿瘤患者术后的生存率<sup>[75]</sup>。Awad等<sup>[76]</sup>研究发现发生SSI的患者比未发生SSI患者的生存率下降了4个月。有研究认为在发生SSI的患者中,38~75%的死亡可归因于SSI本身<sup>[76]</sup>。

2.转移性脊柱肿瘤SSI的危险因素:高龄、糖尿病、吸烟史、低白蛋白水平、术前使用类固醇、用不可吸收缝线缝合、手术时间≥4 h、术中出血≥2000 ml、多发脊柱转移灶、高ASA评分、术前神经功能损害、多节段固定手术、术前放疗等<sup>[1,6,73,75,77-78]</sup>。最近的研究结果表明ASA≥3、手术时间≥4 h、糖尿病和术前放疗是转移性脊柱肿瘤患者发生SSI的独立危险因素<sup>[73,75]</sup>。

为降低SSI的发生率,外科医生应警惕任何感染的迹象和症状,如肿胀、触痛、红斑、持续疼痛、恶心、食欲不振和疲劳等<sup>[29]</sup>。围手术期血糖控制和预防性抗生素的使用已被证明可以减少脊柱手术中伤口感染的发生率<sup>[79]</sup>。对于辅助放疗技术的使用,Itshayek等<sup>[80]</sup>认为术前或术后辅助放疗最佳间隔时间应至少为一周,以减少伤口并发症的发生。Demura等<sup>[73]</sup>发现PGE1可显著降低术前接受放射治疗的脊柱转移患者SSI的发生率。

3.静脉血栓栓塞(Venous thromboembolism, VTE): VTE是癌症患者死亡的主要原因之一,包括深静脉血栓形成(Deep vein thrombosis, DVT)和肺栓塞(Pulmonary embolism, PE)<sup>[81-84]</sup>。与没有癌症的患者相比,癌症患者有47倍的风险发展为症状性VTE<sup>[85-86]</sup>。脊柱手术被认为是症状性VTE的独立危险因素<sup>[87-88]</sup>。此外,接受手术治疗的转移性脊柱肿瘤患者发生VTE的风险比其他需要手术的脊柱疾病(如椎间盘突出症或脊柱畸形)高<sup>[89]</sup>。文献中关于转移性脊柱肿瘤患者术后发生VTE的发生率不尽相同(从6.2%~16.9%不等),可能是由于研究方案、检测方法和研究人群的差异等造成的<sup>[81,84,90]</sup>。Groot等<sup>[84]</sup>报道的一项回顾性分析中637例转移性脊柱肿瘤患者接受手术治疗后90天内症状性VTE的发生率为11%(其中DVT为6.2%,PE为6.0%)。此外,该研究还表明VTE与术后1年的生存率下降相关。另一项回顾性分析研究中647例转移性脊柱肿瘤患者接受手术治疗后30 d内VTE的发生率为6.2%(其中DVT为4.5%,PE为3.6%)<sup>[90]</sup>。

多种因素可能与VTE的高发生率有关,包括高龄、肿瘤、严重的静脉淤滞、术后长时间的卧床等<sup>[87,91-92]</sup>。此外,Kim等<sup>[93]</sup>发现明较长的手术时间与较高的VTE的风险直接相关。目前,对于接受手术治疗的转移性脊柱肿瘤患者来说,仍然缺乏标准的指导方针和防治方案<sup>[81]</sup>。转移性脊柱肿瘤在手术干预后的第1天至第3天,除机械预防外,预防性应用抗凝剂可显著降低30 d内发生VTE的风险<sup>[81]</sup>。虽然需要在更大规模的前瞻性随机对照试验中进一步的研究,但这些发现表



明,早期预防性应用抗凝剂是一种相对安全的做法,可以降低地降低血栓栓塞事件的风险。

4.内固定失败:许多脊柱转移瘤患者需要内固定来维持脊柱的稳定性和神经功能。伴随而来的是内固定失败的风险,这可能会导致再手术、再入院,在严重的情况下,还会导致神经系统的损害或死亡<sup>[94]</sup>。无内固定失败患者的平均生存时间几乎是有内固定失败患者的两倍<sup>[95]</sup>。据文献报道,转移性脊柱肿瘤患者的内固定失败率从1.8%到16%不等<sup>[22,95-101]</sup>。这种差异可能部分是由于患者情况、手术方法和重建方式的不同。

Amankulor等<sup>[97]</sup>确定了内固定失败的危险因素,包括肋骨切除后胸壁不稳定、跨越六个或多个相邻椎体长度的固定以及女性转移性硬膜外脊髓压迫的患者。Longo等<sup>[94]</sup>认为多发性骨髓瘤及美国东部肿瘤协作组评分(Eastern Cooperative Oncology Group score, ECOG) > 2是内固定失败的危险因素。Pedreira等<sup>[95]</sup>发现术前放疗与内固定失败有显著的相关性。既往研究已经证明放疗会导致骨坏死和纤维化<sup>[102-103]</sup>。也有证据表明术前放疗与术后椎旁肌肉愈合不良有关,这些肌肉群的力量下降使脊柱结构承受更大的压力,因此可能进一步导致内固定失败<sup>[104]</sup>。值得注意的是,术后放疗与手术治疗相结合可改善患者的生存质量<sup>[105-107]</sup>。因此,放疗的时机似乎会影响这一患者群体的预后,如果术前进行放疗,必须高度重视内固定失败的风险<sup>[95]</sup>。活动能力受损与内固定风险增加有关,因此,保证患者早期活动不仅可以缩短住院时间和减少术后并发症,还可以降低内固定失败的风险<sup>[94,108]</sup>。

5.肿瘤复发:随着治疗水平的提高,转移性脊柱患者的生存期延长,术后肿瘤复发率也不断增加<sup>[109]</sup>。肿瘤复发可压迫神经或脊髓导致脊柱不稳定和神经/脊髓压迫,严重影响患者的生活质量<sup>[110]</sup>。所有接受手术的转移性脊柱肿瘤患者应密切监测肿瘤的局部复发、活检通道的复发和远处转移。任何可疑的复发应密切关注,必要时进行活检,并及时治疗<sup>[40]</sup>。据文献报道,转移性脊柱肿瘤的术后复发率在5.5%~32.3%<sup>[12,14,111-114]</sup>。Lau等<sup>[111]</sup>随访99例患者转移性脊柱肿瘤患者,其中32例(32.3%)患者在初次手术后出现转移性疾病的局部复发,平均复发时间为9.8个月。Weigel等<sup>[112]</sup>对76例有症状性脊柱转移的患者进行了评估,17例(22%)患者术后出现肿瘤复发,平均复发时间为11.4个月。Lee等<sup>[12]</sup>回顾性分析了200例接受手术治疗的脊柱转移瘤患者,其中11例患者复发(8例原位复发,3例其他部位再发)。

目前的文献中已确定某些癌症类型,如肾癌明显与较高的复发率相关<sup>[112,115]</sup>。Chataigner等<sup>[115]</sup>认为肾癌脊柱转移有高发复发的危险,必须进行全椎体切除术。Lau等<sup>[111]</sup>的研究表明复发率较高的癌症包括肾细胞癌(63.6%)、平滑肌肉瘤(62.5%)、黑色素瘤(50.0%)、甲状腺(50.0%)。但是,通过多变量分析进行分层并对系统转移性疾病进行调整时,发现黑色素瘤是唯一与局部复发独立相关的癌症类型。转移性黑色素瘤和转移性肾细胞瘤的共同之处在于,它们都是非常严重的血管病变<sup>[111]</sup>。目前尚不清楚这些转移病灶的血管分布

是否增加了局部复发的风险。但是,有分子证据表明,在多种肿瘤类型中,血管生成的高水平与较高的复发率相关<sup>[116-117]</sup>。此外,与生存率增加相关的某些因素,包括年龄小于65岁、单一节段椎体转移、化疗、放疗等,与局部复发风险增加相关<sup>[111]</sup>,可能与这些因素与患者生存期延长有关<sup>[112,118]</sup>。

6.其他:除以上常见的并发症之外,文献中报道较少的并发症还包括围术期死亡<sup>[90]</sup>、血管事件(术中心脏骤停、心肌梗塞、心律失常和中风等)<sup>[25,119]</sup>、肺部及呼吸道并发症(胸腔积液、气胸、肺炎、肺脓肿和肺不张等)<sup>[17,18,22,36,42,44,120-121]</sup>、胃肠道并发症(胃溃疡、麻痹性肠梗阻、胃肠道出血等)<sup>[14,22,36,122]</sup>、肝功能衰竭<sup>[12]</sup>、邻近器官损伤(食管、气管、输尿管等)<sup>[40,123]</sup>、腹膜后出血<sup>[124]</sup>、脑膜炎<sup>[12]</sup>、高钙血症征象<sup>[125]</sup>、败血症<sup>[127]</sup>等。

降低手术相关的并发症发生率对转移性脊柱肿瘤患者治疗的成功至关重要。Patil等<sup>[10]</sup>对1993年至2002年在美国接受手术治疗的26 233例脊柱转移瘤患者死亡率、并发症及住院费用等进行分析,术后发生一例并发症,平均住院时间从10 d增加到17 d,死亡率从3%增加到14%,住院费用增加2万美元。Lau等<sup>[126]</sup>报道,发生并发症的患者的住院费用约为无并发症患者的两倍。随着过高的医疗成本成为一个日益紧迫的公共卫生问题,针对性减少手术相关并发症的必要性是显而易见的。

#### 四、总结

转移性脊柱肿瘤的治疗需要多学科诊疗团队针对患者的个体情况共同制定个性化治疗方案,其中先进的外科技术大大改善了患者的生活质量。外科医生必须权衡手术治疗的高并发症发生率与手术治疗带来的益处,否则患者可能会经历不必要的手术,缩短患者的寿命,降低患者的生活质量。此外,术前充分的准备、术中精细的操作、术后密切的观察和及时的处理是降低手术并发症和改善患者预后的关键。

#### 参 考 文 献

- 1 Atkinson RA, Jones A, Ousey K, et al. Management and cost of surgical site infection in patients undergoing surgery for spinal metastasis [J]. J Hosp Infect, 2017, 95(2): 148-153.
- 2 Quraishi NA, Rajabian A, Spencer A, et al. Reoperation rates in the surgical treatment of spinal metastases [J]. Spine J, 2015, 15: S37-43.
- 3 Yahanda AT, Buchowski JM, Wegner AM. Treatment, complications, and outcomes of metastatic disease of the spine: from Patchell to PROMIS [J]. Ann Transl Med, 2019, 7(10): 216.
- 4 Yao A, Sarkiss CA, Ladner TR, et al. Contemporary spinal oncology treatment paradigms and outcomes for metastatic tumors to the spine: A systematic review of breast, prostate, renal, and lung metastases [J]. J Clin Neurosci, 2017, 41: 11-23.
- 5 Zhang HR, Xu MY, Yang XG, et al. Percutaneous vertebral augmentation procedures in the management of spinal metastases [J]. Cancer Lett, 2020, 475: 136-142.
- 6 Luksanaprukha P, Buchowski JM, Zebala LP, et al. Perioperative complications of spinal metastases surgery [J]. Clin Spine Surg, 2017, 30(1): 4-13.
- 7 Laufer I, Sciubba DM, Madera M, et al. Surgical management of

- metastatic spinal tumors [J]. *Cancer Control*, 2012, 19: 122-128
- 8 Fournay DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group [J]. *J Clin Oncol*, 2011, 29(22): 3072-3077.
- 9 Schairer WW, Carrer A, Sing DC, et al. Hospital readmission rates after surgical treatment of primary and metastatic tumors of the spine [J]. *Spine (Phila Pa 1976)*, 2014, 39: 1801-1808.
- 10 Patil CG, Lad SP, Santarelli J, et al. National inpatient complications and outcomes after surgery for spinal metastasis from 1993-2002 [J]. *Cancer*, 2007, 110(3): 625-630.
- 11 Quraishi N, Gokaslan ZL, Boriani S. The surgical management of metastatic epidural compression of the spinal cord [J]. *J Bone Joint Surg Br*, 2010, 92(8): 1054-1060.
- 12 Lee BH, Park JO, Kim HS, et al. Perioperative complication and surgical outcome in patients with spine metastases: retrospective 200-case series in a single institute [J]. *Clin Neurol Neurosurg*, 2014, 122: 80-86.
- 13 Chong S, Shin SH, Yoo H, et al. Single-stage posterior decompression and stabilization for metastasis of the thoracic spine: prognostic factors for functional outcome and patients' survival [J]. *Spine J*, 2012, 12(12): 1083-1092.
- 14 Ohashi M, Hirano T, Watanabe K, et al. En bloc spondylectomy for spinal metastases: detailed oncological outcomes at a minimum of 2 years after surgery [J]. *Asian Spine J*, 2019, 13(2): 296-304.
- 15 Park JH, Jeon SR. Pre- and postoperative lower extremity motor power and ambulatory status of patients with spinal cord compression due to a metastatic spinal tumor [J]. *Spine (Phila Pa 1976)*, 2013, 38(13): E798-E802.
- 16 Park JH, Rhim SC, Jeon SR. Efficacy of decompression and fixation for metastatic spinal cord compression: analysis of factors prognostic for survival and postoperative ambulation [J]. *J Korean Neurosurg Soc*, 2011, 50(5): 434-440.
- 17 Park SJ, Lee CS, Chung SS. Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication [J]. *Spine J*, 2016, 16(3): 322-328.
- 18 Quraishi N, Manoharan SR, Arealis G, et al. Accuracy of the revised Tokunashi score in predicting survival in patients with metastatic spinal cord compression (MSCC) [J]. *Eur Spine J*, 2013, 22 Suppl 1 (Suppl 1): S21-S26.
- 19 Quraishi N, Arealis G, Salem KM, et al. The surgical management of metastatic spinal tumors based on an Epidural Spinal Cord Compression (ESCC) scale [J]. *Spine J*, 2015, 15(8): 1738-1743.
- 20 Quraishi N, Rajagopal TS, Manoharan SR, et al. Effect of timing of surgery on neurological outcome and survival in metastatic spinal cord compression [J]. *Eur Spine J*, 2013, 22(6): 1383-1388.
- 21 Vanek P, Bradac O, Trebicky F, et al. Influence of the preoperative neurological status on survival after the surgical treatment of symptomatic spinal metastases with spinal cord compression [J]. *Spine (Phila Pa 1976)*, 2015, 40(23): 1824-1830.
- 22 Wang JC, Boland P, Mitra N, et al. Single-stage posterolateral transpedicular approach for resection of epidural metastatic spine tumors involving the vertebral body with circumferential reconstruction: results in 140 patients. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004 [J]. *J Neurosurg Spine*, 2004, 1: 287-298
- 23 Glicksman RM, Tjong MC, Neves-Junior WFP, et al. stereotactic ablative radiotherapy for the management of spinal metastases: a review [J]. *JAMA Oncol*, 2019: 5351.
- 24 Nater A, Sahgal A, Fehlings M. Management - spinal metastases [J]. *Handb Clin Neurol*, 2018, 149: 239-255.
- 25 Finkelstein JA, Zaveri G, Wai E, et al. A population-based study of surgery for spinal metastases. Survival rates and complications [J]. *J Bone Joint Surg Br*, 2003, 85(7): 1045-1050.
- 26 Onimus M, Papin P, Gangloff S. Results of surgical treatment of spinal thoracic and lumbar metastases [J]. *Eur Spine J*, 1996, 5(6): 407-411.
- 27 Wibmer C, Leithner A, Hofmann G, et al. Survival analysis of 254 patients after manifestation of spinal metastases: evaluation of seven preoperative scoring systems [J]. *Spine (Phila Pa 1976)*, 2011, 36(23): 1977-1986.
- 28 肖建如. 脊柱转移瘤的外科治疗进展 [J]. *中国癌症杂志*, 2012, 09(003): 652-657.
- 29 Igoumenou VG, Mavrogenis AF, Angelini A, et al. Complications of spine surgery for metastasis [J]. *Eur J Orthop Surg Traumatol*, 2020, 30: 37-56.
- 30 Bilsky MH, Boland P, Lis E, et al. Single-stage posterolateral transpedicle approach for spondylectomy, epidural decompression, and circumferential fusion of spinal metastases [J]. *Spine (Phila Pa 1976)*, 2000, 25(17): 2240-2249, discussion 250.
- 31 Sakaura H, Hosono N, Mukai Y, et al. Outcome of total en bloc spondylectomy for solitary metastasis of the thoracolumbar spine [J]. *J Spinal Disord Tech*, 2004, 17(4): 297-300.
- 32 韩秀鑫, 王国文, 张超, 等. 121例脊柱转移瘤手术治疗的疗效分析 [J]. *中华骨科杂志*, 2014, 34: 1127-1133.
- 33 Lau D, Leach MR, Than KD, et al. Independent predictors of complication following surgery for spinal metastasis [J]. *Eur Spine J*, 2013, 22(6): 1402-1407.
- 34 Yang W, Jiang L, Liu X, et al. Surgical complications of extraspinal tumors in the cervical spine: a report of 110 cases and literature review [J]. *Eur Spine J*, 2018, 27(4): 882-890.
- 35 Liang T, Wan Y, Zou X, et al. Is surgery for spine metastasis reasonable in patients older than 60 years? [J]. *Clin Orthop Relat Res*, 2013, 471(2): 628-639.
- 36 Ju DG, Zadnik PL, Groves ML, et al. Factors associated with improved outcomes following decompressive surgery for prostate cancer metastatic to the spine [J]. *Neurosurgery*, 2013, 73(4): 657-666; discussion 666.
- 37 Galgano M, Fridley J, Oyelese A, et al. Surgical management of spinal metastases [J]. *Expert Rev Anticancer Ther*, 2018, 18: 463-472.
- 38 Loblaw DA, Mitera G, Ford M, et al. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression [J]. *Int J Radiat Oncol Biol Phys*, 2012, 84(2): 312-317.
- 39 Scibilia A, Raffa G, Rizzo V, et al. Intraoperative neurophysiological monitoring in spine surgery: a significant Tool for neuronal protection and functional restoration [J]. *Acta Neurochir Suppl*, 2017, 124: 263-270.
- 40 Clarke MJ, Vrionis FD. Spinal tumor surgery: management and the avoidance of complications [J]. *Cancer Control*, 2014, 21(2): 124-132.
- 41 Qiao Z, Jia N, He Q. Does preoperative transarterial embolization decrease blood loss during spine tumor surgery? [J]. *Interv Neuroradiol*, 2015, 21(1): 129-135.

- 42 Gao X, Fan T, He S, et al. A Useful Model for Predicting Intraoperative Blood Loss in Metastatic Spine Tumor Surgery [J]. *Clinical spine surgery*, 2020, 33: 256-262
- 43 Abe E, Kobayashi T, Murai H, et al. Total spondylectomy for primary malignant, aggressive benign, and solitary metastatic bone tumors of the thoracolumbar spine [J]. *J Spinal Disord*, 2001, 14(3): 237-246.
- 44 Chen YJ, Chang GC, Chen HT, et al. Surgical results of metastatic spinal cord compression secondary to non-small cell lung cancer [J]. *Spine (Phila Pa 1976)*, 2007, 32(15): E413-E418.
- 45 Cho DC, Sung JK. Palliative surgery for metastatic thoracic and lumbar tumors using posterolateral transpedicular approach with posterior instrumentation [J]. *Surg Neurol*, 2009, 71(4): 424-433.
- 46 Street J, Fisher C, Sparkes J, et al. Single-stage posterolateral vertebrectomy for the management of metastatic disease of the thoracic and lumbar spine: a prospective study of an evolving surgical technique [J]. *J Spinal Disord Tech*, 2007, 20(7): 509-520.
- 47 Tanaka M, Nakahara S, Ito Y, et al. Surgical treatment of metastatic vertebral tumors [J]. *Acta Med Okayama*, 2009, 63: 145-150.
- 48 C Olerud, H Jonsson, AM Lofberg, et al. Embolization of spinal metastases reduces perioperative blood loss. 21 patients operated on for renal cell carcinoma [J]. *Acta Orthop Scand*, 1993, 64(1): 9-12.
- 49 Schmidt R, Rupp-Heim G, Dammann F, et al. Surgical therapy of vertebral metastases. Are there predictive parameters for intraoperative excessive blood loss despite preoperative embolization? [J]. *Tumori*, 2011, 97(1): 66-73.
- 50 Molina CA, Gokaslan ZL, Sciubba DM. Diagnosis and management of metastatic cervical spine tumors [J]. *Orthop Clin North Am*, 2012, 43(1): 75-87, viii-ix.
- 51 Bilsky MH, Fraser JF. Complication avoidance in vertebral column spine tumors [J]. *Neurosurg Clin N Am*, 2006, 17(3): 317-329, vii.
- 52 Ghobrial GM, Theofanis T, Darden BV, et al. Unintended durotomy in lumbar degenerative spinal surgery: a 10-year systematic review of the literature [J]. *Neurosurg Focus*, 2015, 39(4): E8.
- 53 Mayfield FH, Kurokawa K. Watertight closure of spinal dura mater. Technical note [J]. *J Neurosurg*, 1975, 43(5): 639-640.
- 54 Rodriguez-Olaverri JC, Zimic NC, Merola A, et al. Comparing the clinical and radiological outcomes of pedicular transvertebral screw fixation of the lumbosacral spine in spondylolisthesis versus unilateral transforaminal lumbar interbody fusion (TLIF) with posterior fixation using anterior cages [J]. *Spine (Phila Pa 1976)*, 2008, 33(18): 1977-1981.
- 55 Wang JC, Bohlman HH, Riew KD. Dural tears secondary to operations on the lumbar spine. Management and results after a two-year-minimum follow-up of eighty-eight patients [J]. *J Bone Joint Surg Am*, 1998, 80(12): 1728-1732.
- 56 Fehlings MG, David KS, Vialle L, et al. Decision making in the surgical treatment of cervical spine metastases [J]. *Spine (Phila Pa 1976)*, 2009, 34(22 Suppl): S108-S117.
- 57 Tosun B, Ilbay K, Kim MS, et al. Management of persistent cerebrospinal fluid leakage following thoraco-lumbar surgery [J]. *Asian Spine J*, 2012, 6(3): 157-162.
- 58 Jenkinson MD, Simpson C, Nicholas RS, et al. Outcome predictors and complications in the management of intradural spinal tumours [J]. *Eur Spine J*, 2006, 15(2): 203-210.
- 59 Ropper AE, Huang KT, Ho AL, et al. Intraoperative cerebrospinal fluid leak in extradural spinal tumor surgery [J]. *Neurospine*, 2018, 15(4): 338-347.
- 60 Chan SM, Chodakiewitz YG, Maya MM, et al. Intracranial hypotension and cerebrospinal fluid leak [J]. *Neuroimaging Clin N Am*, 2019, 29(2): 213-226.
- 61 Kaloostian PE, Kim JE, Bydon A, et al. Intracranial hemorrhage after spine surgery [J]. *J Neurosurg Spine*, 2013, 19: 370-380
- 62 Yoo JC, Choi JJ, Lee DW, et al. Remote cerebellar hemorrhage after intradural disc surgery [J]. *J Korean Neurosurg Soc*, 2013, 53(2): 118-120.
- 63 Fernandez-Jara J, Jorge-Blanco A, Carro-Martinez A, et al. Remote cerebellar hemorrhage after lumbar spinal surgery [J]. *Emerg Radiol*, 2011, 18(2): 177-180.
- 64 Clarke MJ, Krauss WE. Cerebrospinal fluid happens [J]. *World Neurosurg*, 2015, 83(3): 308-310.
- 65 Hawk MW, Kim KD. Review of spinal pseudomeningoceles and cerebrospinal fluid fistulas [J]. *Neurosurg Focus*, 2000, 9(1): e5.
- 66 O'Connor D, Maskery N, Griffiths WE. Pseudomeningocele nerve root entrapment after lumbar discectomy [J]. *Spine (Phila Pa 1976)*, 1998, 23(13): 1501-1502.
- 67 Oterdoom DL, Groen RJ, Coppes MH. Cauda equina entrapment in a pseudomeningocele after lumbar schwannoma extirpation [J]. *Eur Spine J*, 2010, 19 Suppl 2(Suppl 2): S158-S161.
- 68 Lin TY, Chen WJ, Hsieh MK, et al. Postoperative meningitis after spinal surgery: a review of 21 cases from 20,178 patients [J]. *BMC Infect Dis*, 2014, 14: 220.
- 69 Barber SM, Fridley JS, Konakondla S, et al. Cerebrospinal fluid leaks after spine tumor resection: avoidance, recognition and management [J]. *Ann Transl Med*, 2019, 7(10): 217.
- 70 Bydon M, Macki M, Xu R, et al. Spinal decompression in achondroplastic patients using high-speed drill versus ultrasonic bone curette: technical note and outcomes in 30 cases [J]. *J Pediatr Orthop*, 2014, 34(8): 780-786.
- 71 Bydon M, Xu RS, Papademetriou K, et al. Safety of spinal decompression using an ultrasonic bone curette compared with a high-speed drill: outcomes in 337 patients [J]. *J Neurosurg Spine*, 2013, 18(6): 627-633.
- 72 Weber C, Piek J, Gunawan D. Health care costs of incidental durotomies and postoperative cerebrospinal fluid leaks after elective spinal surgery [J]. *Eur Spine J*, 2015, 24(9): 2065-2068.
- 73 Demura S, Kawahara N, Murakami H, et al. Surgical site infection in spinal metastasis: risk factors and countermeasures [J]. *Spine (Phila Pa 1976)*, 2009, 34(6): 635-639.
- 74 Sebaaly A, El RR, Yaacoub JJ, et al. Management of spinal infections in children with cerebral palsy [J]. *Orthop Traumatol Surg Res*, 2016, 102(6): 801-805.
- 75 Sebaaly A, Shedid D, Boubes G, et al. Surgical site infection in spinal metastasis: incidence and risk factors [J]. *Spine J*, 2018, 18(8): 1382-1387.
- 76 Awad SS. Adherence to surgical care improvement project measures and post-operative surgical site infections [J]. *Surg Infect (Larchmt)*, 2012, 13(4): 234-237.
- 77 Kumar S, van Popta D, Rodrigues-Pinto R, et al. Risk factors for wound infection in surgery for spinal metastasis [J]. *Eur Spine J*, 2015, 24: 528-532
- 78 McPhee IB, Williams RP, Swanson CE. Factors influencing wound healing after surgery for metastatic disease of the spine [J]. *Spine (Phila Pa 1976)*, 1998, 23(6): 726-732; discussion 732-3.
- 79 Swann MC, Hoes KS, Aoun SG, et al. Postoperative complications

- of spine surgery [J]. *Best Pract Res Clin Anaesthesiol*, 2016, 30(1): 103-120.
- 80 Itshayek E, Yamada J, Bilsky M, et al. Timing of surgery and radiotherapy in the management of metastatic spine disease: a systematic review [J]. *Int J Oncol*, 2010, 36(3): 533-544.
- 81 De La Garza RR, Longo M, Gelfand Y, et al. Timing of prophylactic anticoagulation and its effect on thromboembolic events after surgery for metastatic tumors of the spine [J]. *Spine (Phila Pa 1976)*, 2019, 44(11): E650-E655.
- 82 Caine GJ, Stonelake PS, Lip GY, et al. The hypercoagulable state of malignancy: pathogenesis and current debate [J]. *Neoplasia*, 2002, 4(6): 465-473.
- 83 Rickles FR, Levine MN. Epidemiology of thrombosis in cancer [J]. *Acta Haematol*, 2001, 106(1/2): 6-12.
- 84 Groot OQ, Ogink PT, Paulino PN, et al. High risk of symptomatic venous thromboembolism after surgery for spine metastatic bone lesions: a retrospective study [J]. *Clin Orthop Relat Res*, 2019, 477(7): 1674-1686.
- 85 Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis [J]. *JAMA*, 2005, 293(6): 715-722.
- 86 Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study [J]. *Arch Intern Med*, 2000, 160(6): 809-815.
- 87 Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) [J]. *Chest*, 2008, 133(6 Suppl): 381S-453S.
- 88 Clagett GP, Anderson FA, Geerts W, et al. Prevention of venous thromboembolism [J]. *Chest*, 1998, 114: 531S-560S.
- 89 Yoshioka K, Murakami H, Demura S, et al. Comparative study of the prevalence of venous thromboembolism after elective spinal surgery [J]. *Orthopedics*, 2013, 36(2): e223-e228.
- 90 Paulino PN, Ogink PT, Groot OQ, et al. Complications and reoperations after surgery for 647 patients with spine metastatic disease [J]. *Spine J*, 2019, 19(1): 144-156.
- 91 Al-Dujaili TM, Majer CN, Madhoun TE, et al. Deep venous thrombosis in spine surgery patients: incidence and hematoma formation [J]. *Int Surg*, 2012, 97(2): 150-154.
- 92 Glotzbecker MP, Bono CM, Wood KB, et al. Thromboembolic disease in spinal surgery: a systematic review [J]. *Spine (Phila Pa 1976)*, 2009, 34(3): 291-303.
- 93 Kim JY, Khavanin N, Rambachan A, et al. Surgical duration and risk of venous thromboembolism [J]. *JAMA Surg*, 2015, 150(2): 110-117.
- 94 Longo M, De la Garza Ramos R, Gelfand Y, et al. Incidence and Predictors of Hardware Failure After Instrumentation for Spine Metastasis: A Single-Institutional Series [J]. *World Neurosurg*, 2019, 125: e1170-e1175.
- 95 Pedreira R, Abu-Bonsrah N, Karim Ahmed A, et al. Hardware failure in patients with metastatic cancer to the spine [J]. *J Clin Neurosci*, 2017, 45: 166-171.
- 96 Akeyson EW, Mccutcheon IE. Single-stage posterior vertebrectomy and replacement combined with posterior instrumentation for spinal metastasis [J]. *J Neurosurg*, 1996, 85(2): 211-220.
- 97 Amankulor NM, Xu R, Iorgulescu JB, et al. The incidence and patterns of hardware failure after separation surgery in patients with spinal metastatic tumors [J]. *Spine J*, 2014, 14(9): 1850-1859.
- 98 De Ruiter GC, Lobatto DJ, Wolfs JF, et al. Reconstruction with expandable cages after single- and multilevel corpectomies for spinal metastases: a prospective case series of 60 patients [J]. *Spine J*, 2014, 14(9): 2085-2093.
- 99 Heidecke V, Rainov NG, Burkert W. Results and outcome of neurosurgical treatment for extradural metastases in the cervical spine [J]. *Acta Neurochir (Wien)*, 2003, 145(10): 873-880; discussion 880-1.
- 100 Jandial R, Kelly B, Chen MY. Posterior-only approach for lumbar vertebral column resection and expandable cage Reconstruction for spinal metastases [J]. *J Neurosurg Spine*, 2013, 19(1): 27-33.
- 101 Vrionis FD, Small J. Surgical management of metastatic spinal neoplasms [J]. *Neurosurg Focus*, 2003, 15(5): E12.
- 102 Donovan DJ, Huynh TV, Purdom EB, et al. Osteoradionecrosis of the cervical spine resulting from radiotherapy for primary head and neck malignancies: operative and nonoperative management. Case report [J]. *J Neurosurg Spine*, 2005, 3(2): 159-164.
- 103 Palejwala SK, Lawson KA, Kent SL, et al. Lumbar corpectomy for correction of degenerative scoliosis from osteoradionecrosis reveals a delayed complication of lumbar myxopapillary ependymoma [J]. *J Clin Neurosci*, 2016, 30: 160-162.
- 104 Kim JB, Park SW, Lee YS, et al. The effects of spinopelvic parameters and paraspinal muscle degeneration on S1 screw loosening [J]. *J Korean Neurosurg Soc*, 2015, 58(4): 357-362.
- 105 Ibrahim A, Crookard A, Antonietti P, et al. Does spinal surgery improve the quality of life for those with extradural (spinal) osseous metastases? An international multicenter prospective observational study of 223 patients. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2007 [J]. *J Neurosurg Spine*, 2008, 8(3): 271-278.
- 106 Kaloostian PE, Zadnik PL, Etame AB, et al. Surgical management of primary and metastatic spinal tumors [J]. *Cancer Control*, 2014, 21(2): 133-139.
- 107 Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial [J]. *Lancet*, 2005, 366(9486): 643-648.
- 108 Epstein NE. A review article on the benefits of early mobilization following spinal surgery and other medical/surgical procedures [J]. *Surg Neurol Int*, 2014, 5(Suppl 3): S66-S73.
- 109 Rajah G, Rapp A, Discolo E, et al. Surgical decompression for recurrent cord compression in cancer: a case series and review of the literature [J]. *Neurol Res*, 2018, 40(7): 549-554.
- 110 Rajah G, Rapp A, Discolo E, et al. Surgical decompression for recurrent cord compression in cancer: a case series and review of the literature [J]. *Neurological research*, 2018, 40: 549-554.
- 111 Lau D, Than KD, La Marca F, et al. Independent predictors for local recurrence following surgery for spinal metastasis [J]. *Acta Neurochir (Wien)*, 2014, 156(2): 277-282.
- 112 Weigel B, Maghsudi M, Neumann C, et al. Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of Life [J]. *Spine (Phila Pa 1976)*, 1999, 24(21): 2240-2246.
- 113 Van Der Sande JJ, Boogerd W, Kröger R, et al. Recurrent spinal epidural metastases: a prospective study with a complete follow up [J]. *J Neurol Neurosurg Psychiatry*, 1999, 66(5): 623-627.
- 114 Aizenberg MR, Fox BD, Suki D, et al. Surgical management of unknown primary tumors metastatic to the spine [J]. *J Neurosurg Spine*, 2012, 16(1): 86-92.



- 115 Chataigner H, Onimus M. Surgery in spinal metastasis without spinal cord compression: indications and strategy related to the risk of recurrence [J]. *Eur Spine J*, 2000, 9(6): 523-527.
- 116 Lassau N, Lamuraglia M, Koscielny S, et al. Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period [J]. *Cancer Imaging*, 2006, 6(1): 24-29.
- 117 Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy [J]. *Clin Cancer Res*, 2000, 6(12): 4866-4873.
- 118 Lau D, Leach MR, La Marca F, et al. Independent predictors of survival and the impact of repeat surgery in patients undergoing surgical treatment of spinal metastasis [J]. *J Neurosurg Spine*, 2012, 17(6): 565-576.
- 119 Zanirato A, Damilano M, Formica M, et al. Complications in adult spine deformity surgery: a systematic review of the recent literature with reporting of aggregated incidences [J]. *Eur Spine J*, 2018, 27(9): 2272-2284.
- 120 Rades D, Huttenlocher S, Evers JN, et al. Do elderly patients benefit from surgery in addition to radiotherapy for treatment of metastatic spinal cord compression? [J]. *Strahlenther Onkol*, 2012, 188(5): 424-430.
- 121 Smetana GW. Preoperative pulmonary evaluation: identifying and reducing risks for pulmonary complications [J]. *Cleve Clin J Med*, 2006, 73 Suppl 1: S36-S41.
- 122 Luksanaprukha P, Buchowski JM, Tongsai S, et al. Systematic review and meta-analysis of effectiveness of preoperative embolization in surgery for metastatic spine disease [J]. *J Neurointerv Surg*, 2018, 10(6): 596-601.
- 123 Chung KC, Lin CH, Tsai CL, et al. Tracheomalacia as complication of stenting for esophageal injury after transsternal approach to high thoracic vertebral metastasis [J]. *World Neurosurg*, 2019, 125: 67-71.
- 124 Chaichana KL, Woodworth GF, Sciubba DM, et al. Predictors of ambulatory function after decompressive surgery for metastatic epidural spinal cord compression [J]. *Neurosurgery*, 2008, 62(3): 683-692; discussion 683-92.
- 125 Szczerba P. Complications after Surgical Treatment of Spinal Metastases [J]. *Ortop Traumatol Rehabil*, 2019, 21(1): 23-31.
- 126 Lau D, Chan AK, Theologis AA, et al. Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients [J]. *J Neurosurg Spine*, 2016, 25(3): 366-378.
- (收稿日期:2019-11-04)  
(本文编辑:吕红芝)

胡宏志, 杨文博, 邓翔天, 等. 转移性脊柱肿瘤的手术并发症和预防策略 [J/CD]. 中华老年骨科与康复电子杂志, 2021, 7(1): 52-59.